A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life

BACKGROUND: Approximately 20% to 40% of patients with gastroesophageal reflux disease (GERD) are refractory to standard-dose proton-pump inhibitor (PPI) treatment. OBJECTIVE: We compared the efficacy and quality-of-life effects of 20 mg once daily (QD) versus 10 mg twice daily (BID) rabeprazole (RPZ...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuki, Akira, Tatemichi, Masayuki, Sakakibara, Terue, Miura, Yukihiko, Zeki, Shigeyuki, Ohata, Mitsuru, Matsuo, Kenji, Kawamura, Fumio, Nagata, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200872/
https://www.ncbi.nlm.nih.gov/pubmed/28066515
http://dx.doi.org/10.1016/j.curtheres.2016.11.002

Ejemplares similares

Ejemplares similares